{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihefc7fv5hdmwoddtevs36u72zi7itdxd27qf2kzz4xt64bolctim",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjxsj7fxdtq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifmugp5qu4gnhfs653t4t34mq6ng3hzgubji7ijarw75wnoh2bree"
    },
    "mimeType": "image/jpeg",
    "size": 187067
  },
  "path": "/news/2026-04-aacr-zedoresertib-lunresertib-combination-antitumor.html",
  "publishedAt": "2026-04-20T20:00:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib demonstrated promising antitumor activity and was generally well-tolerated, according to Phase I MYTHIC trial data reported by researchers at The University of Texas MD Anderson Cancer Center.",
  "title": "AACR: Zedoresertib and lunresertib combination shows promising antitumor activity"
}